Non–Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction

Journal of the American College of Cardiology

Volumn 69, Issue 23, 2017, Pages 2779-2790

  Yao, Xiaoxi ^a   Shah, Nilay D ^a,b   Sangaralingham, Lindsey R ^a   Gersh, Bernard J ^a   Noseworthy, Peter A ^a  

^a MAYO CLINIC   (United States)

^b OPTUM   (United States)

Author keywords

bleeding; dose; embolism; kidney disease; stroke

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; CREATININE; DABIGATRAN; RIVAROXABAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG UNDERDOSE; EMBOLISM; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES; VERY ELDERLY; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DOSE RESPONSE; FOLLOW UP; HEMORRHAGE; INCIDENCE; KIDNEY FAILURE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RETROSPECTIVE STUDY; STROKE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RIVAROXABAN; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VITAMIN K; YOUNG ADULT;

EID: 85020240487     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.03.600     Document Type: Article

References (30)

1. Wolf, P.A., Abbott, R.D., Kannel, W.B., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991), 983–988.
2. Granger, C.B., Alexander, J.H., McMurray, J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
3. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
4. Patel, M.R., Mahaffey, K.W., Garg, J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
5. Giugliano, R.P., Ruff, C.T., Braunwald, E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
6. Heidbuchel, H., Verhamme, P., Alings, M., et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
7. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
8. Steinberg, B.A., Holmes, D.N., Piccini, J.P., et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc, 2, 2013, e000535.
9. Camm, A.J., Amarenco, P., Haas, S., et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 37 (2016), 1145–1153.
10. Pokorney, S.D., O'Brien, E.C., Granger, C.B., Assessing generalizability of trial results in general practice. Eur Heart J 37 (2016), 1154–1157.
11. Wallace, P.J., Shah, N.D., Dennen, T., Bleicher, P.A., Crown, W.H., Optum Labs: building a novel node in the learning health care system. Health Aff (Millwood) 33 (2014), 1187–1194.
12. Optum. Optum Research Data Assets. 2015. Available at: https://www.optum.com/content/dam/optum/resources/productSheets/5302_Data_Assets_Chart_Sheet_ISPOR.pdf. Accessed April 8, 2017.
13. Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
14. Austin, P.C., Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 10 (2011), 150–161.
15. Stuart, E.A., Matching methods for causal inference: a review and a look forward. Stat Sci 25 (2010), 1–21.
16. Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28 (2009), 3083–3107.
17. Gayat, E., Resche-Rigon, M., Mary, J.Y., Porcher, R., Propensity score applied to survival data analysis through proportional hazards models: a Monte Carlo study. Pharm Stat 11 (2012), 222–229.
18. Grambsch, P.M., Therneau, T.M., Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994), 515–526.
19. Austin, P.C., Stuart, E.A., Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34 (2015), 3661–3679.
20. Prasad, V., Jena, A.B., Prespecified falsification end points: can they validate true observational associations?. JAMA 309 (2013), 241–242.
21. Nielsen, P.B., Skjoth, F., Sogaard, M., Kjaeldgaard, J.N., Lip, G.Y., Larsen, T.B., Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ, 356, 2017, j510.
22. Hohnloser, S.H., Hijazi, Z., Thomas, L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 33 (2012), 2821–2830.
23. Lip, G.Y., Keshishian, A., Kamble, S., et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis. Thromb Haemost 116 (2016), 975–986.
24. Graham, D.J., Reichman, M.E., Wernecke, M., et al. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 176 (2016), 1662–1671.
25. Seeger, J., Bykov, K., Bartels, D., Huybrechts, K., Zint, K., Schneeweiss, S., Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 114 (2015), 1277–1289.
26. Wang, S.V., Franklin, J.M., Glynn, R.J., Schneeweiss, S., Eddings, W., Gagne, J.J., Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ, 353, 2016, i2607.
27. Chang, H.Y., Zhou, M., Tang, W., Alexander, G.C., Singh, S., Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ, 350, 2015, h1585.
28. Yao, X., Abraham, N.S., Alexander, G.C., et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc, 5, 2016, e003074.
29. Flamant, M., Haymann, J.P., Vidal-Petiot, E., et al. GFR estimation using the Cockcroft-Gault, MDRD study, and CKD-EPI equations in the elderly. Am J Kidney Dis 60 (2012), 847–849.
30. Michels, W.M., Grootendorst, D.C., Verduijn, M., Elliott, E.G., Dekker, F.W., Krediet, R.T., Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5 (2010), 1003–1009.